Multiple System Atrophy
TEVATeva Pharmaceutical Industries LtdCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Emrusolmin / TEV-’286 in Multiple System Atrophy. The expected timing is based on the latest available company guidance and may change.
Collab. w/ MODAG, ready to start Ph2 in H2 '24 04/29/26:- Management expects meaningful emrusolmin MSA data updates during 2026.
Verification
Confirm timing and program details against the company announcement or filing.